Thursday July 22, 2021 at 11am EDT| 8am PDT| 4pm BST|5pm CEST
Register Free:
Event Overview:
Cancer remains the primary cause of mortality around the globe, and one significant aspect for the development of efficient anticancer drugs in humans is to better understand human cancer biology during the preclinical stage of drug discovery. Researchers are developing effective preclinical models to investigate tumorigenesis and other significant hallmarks of cancer, including sustaining proliferation, evading growth suppressors, resisting cell death, stimulating angiogenesis, activating invasion and metastasis, etc. In this webinar, we will review the currently available robust preclinical cancer models used by the cancer research community, along with an in-depth review of some genotoxic chemical carcinogens.
Key Learning Objectives:
Who Should Attend:
Basic and translational cancer researchers, preclinical pharmacologists, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field.
Speakers
Dr. Sumeet Gullaiya
GTM Manager
Toronto Research Chemicals
Sumeet Gullaiya has completed his PhD (Pharmacology and Toxicology) from Delhi Institute of Pharmaceutical Sciences and Research, India. He has worked as an Assistant Professor in a premier research oriented academic organization. He has published more than 25 papers in reputed journals of national and international repute, authored 3 books, filed 2 patents and is also serving as an Editorial Board Member and Reviewer for reputed journals. Currently, he is working as Product Manager in a leading research chemical manufacturing company, Toronto Research Chemicals (TRC).
Register Free:
